FindTrial
Sign In

GISSI AF Randomized, prospective, parallel group, placebo-controlled, multi-center study on the use of valsartan an angiotensin II AT1-receptor blocker in the prevention of Atrial Fibrillation recurrence

GISSI AF Randomized, prospective, parallel group, placebo-controlled, multi-center study on the use of valsartan an angiotensin II AT1-receptor blocker in the prevention of Atrial Fibrillation recurrence

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-003036-53-IT
Enrollment
1402
Registered
2005-03-03
Start date
2004-10-26
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation Prevention MedDRA version: 6.1 Level: PT Classification code 10003658

Interventions

Trade Name: TAREG 80*80 MG 28 CPS Product Name: NA Product Code: NA Pharmaceutical Form: Capsule, hard INN or Proposed INN: Valsartan CAS Number: 137862-53-4 Concentration unit: mg milligram(s) Concen

Sponsors

A. N. M. C. O. - FONDAZIONE ITALIANA LOTTA MALATTIE CARDIOVASCOLARI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026